European Child & Adolescent Psychiatry

, Volume 14, Issue 6, pp 305–309

12-month efficacy and safety of OROS® MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH


    • Child and Family Mental Health ServiceRoyal Hospital for Sick Children
  • H. Remschmidt
    • Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters
  • R. Medori
    • Janssen-Cilag Europe, Middle-East, Africa
  • C. Ettrich
    • Kinder- und Jugendpsychiatrie der Universität Leipzig, Dritte Etage
  • A. Rothenberger
    • Kinder und Jugendpsychiatrie der Georg-August Universität
  • P. Santosh
    • Maudsley Hospital, Institute of Psychiatry
  • M. Schmit
    • Kinder- und Jugendpsychiatrie Klinik Zentralinstitut für seelische Gesundheit
  • Q. Spender
    • Orchard House Sussex Weald and Downs NHS Trust
  • R. Tamhne
    • Leicestershire and Rutland Healthcare Trust
  • M. Thompson
    • Ashurst Hospital, Department of Psychiatry
  • C. Tinline
    • The Pear Tree Centre Child and Family Therapy Service, Smallwood House
  • G. E. Trott
    • Privatpraxis

DOI: 10.1007/s00787-005-0486-3

Cite this article as:
Hoare, P., Remschmidt, H., Medori, R. et al. Europ.Child & Adolescent Psych (2005) 14: 305. doi:10.1007/s00787-005-0486-3



The aim of this study was to evaluate long-term clinical treatment with OROS® methylphenidate (MPH) (Concerta®) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had been previously treated with immediate release (IR) MPH.


Subjects aged 6–16 years (n=105) who were stable on IR MPH (10–60 mg/day) were switched to 18, 36 or 54mg OROS® MPH once daily for 21 days, depending on prestudy MPH dose. Subjects who benefited from OROS® MPH could continue in a 12-month extension period. ADHD symptoms and treatment response were assessed by parents/caregivers and investigators.


Out of 105 enrolled children, 101 completed the 21-day treatment phase. In all, 89 parents/caregivers (88.1%) wanted their child to continue with the study treatment into the extension phase, and 56 children (63 %) completed the 1-year trial. The parent/caregiver global assessment of satisfaction ranged from 49 to 69% during the extension phase, and 49 to 71% of investigators rated the treatment as adequate. Efficacy and satisfaction were found more commonly in patients in the older age group (10–16 years), those on a higher dose (36 mg or 54 mg) and with the predominantly inattentive ADHD subtype. OROS® MPH was well tolerated.


Children and adolescents can effectively and safely be switched from IR MPH to OROS® MPH with improved symptom control and compliance.

Key words

ADHDCONCERTA®methylphenidateOROS®long-term treatment

Copyright information

© Steinkopff Verlag 2005